NCT04516278 Phase 3 Completed
A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders Study sponsor: Outlook Therapeutics, Inc. · OTLK
Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.
Changes Study details Primary completion 2021-02-10 Actual
Enrollment · participants 197 Actual
Source updated 2026-07-17 Last update listed in the registry record
Version history
Changes to this trial Last 12 months
Posted 2026-07-17 · 1 field changed
Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Compare wording
− Before Measure: Frequency and Incidence of Treatment-emergent Adverse Events
+ After Measure: Number of Participants With Adverse Events
Check registry source
Posted 2026-06-23 · 2 fields changed
Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Compare wording
− Before Measure: Frequency and incidence of treatment-emergent adverse events
+ After Measure: Frequency and Incidence of Treatment -emergent Adverse Events
Actual enrollment increased by 2 participants
− Before 195 participants (actual)
+ After 197 participants (actual)
Check registry source
This database covers selected trials and recorded edits. Some past edits may be missing, and saved text about the main study measures (endpoints) may be shortened. Check the original registry record when a detail matters. Read our methodology
Trial